Prostaglandins, leukotrienes, and medicine · 1984
The combined effects of sodium salicylate, aspirin and indomethacin on the metabolism of arachidonic acid in human platelets.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАПоддержка службы здравоохранения СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dahl M L, Uotila P
Аннотация
The effects of acetylsalicylic acid (ASA, aspirin), indomethacin and sodium salicylate on the metabolism of exogenous 14C-arachidonic acid (AA) were studied in intact human platelets in vitro. ASA (100 microM) and indomethacin (1 and 10 microM) suppressed the metabolism of AA via the cyclo-oxygenase but had no effect on the lipoxygenase pathway. Sodium salicylate at 1 mM was ineffective whereas 2 mM salicylate significantly decreased the formation of TXB2 and HHT and increased that of other cyclo-oxygenase products without clearly affecting total cyclo-oxygenase activity. The formation of 12-HETE, the main metabolite of AA in human platelets, was decreased by 2 mM sodium salicylate as well as by the combination of 1 mM salicylate plus ASA or indomethacin. Pretreatment of platelets with sodium salicylate (1 or 2 mM) effectively prevented the inhibition of the cyclo-oxygenase by ASA (100 microM) but had no effect on the inhibition produced by indomethacin (1 or 10 microM). When sodium salicylate was added to the platelet-containing buffer after ASA or indomethacin it did not reverse the effects of these drugs on the cyclo-oxygenase. The present study suggests that sodium salicylate effectively prevents the inhibitory effect of ASA but not that of indomethacin on human platelet cyclo-oxygenase at the concentrations used. In addition, a high concentration of sodium salicylate (2 mM) may selectively inhibit the formation of TXB2 without clearly affecting total cyclo-oxygenase activity.